Joanna Parkinson

AstraZeneca (Australia) — Australia

Medicine · Health Sciences

13h-index515citations48works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(18), Diabetes Management and Research(12), Pancreatic function and diabetes(12), Cardiac electrophysiology and arrhythmias(9), Gout, Hyperuricemia, Uric Acid(5)

Publications48 total

No Evidence of <scp>QTc</scp> Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment
Pharmacology Research & Perspectives·2025Open Access
Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease
Clinical Pharmacokinetics·2025Open Access
Practical guide to concentration-QTc modeling: a hands-on tutorial
Journal of Pharmacokinetics and Pharmacodynamics·2025
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
British Journal of Clinical Pharmacology·2025· 1 citedOpen Access
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone
British Journal of Clinical Pharmacology·2025· 3 citedOpen Access
The effect of severe renal impairment on the pharmacokinetics, safety, and tolerability of balcinrenone
2024· 1 citedOpen Access
Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval
CPT Pharmacometrics & Systems Pharmacology·2024· 1 citedOpen Access
Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity
Journal of Clinical Research in Pediatric Endocrinology·2024· 6 citedOpen Access
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease
Kidney International·2024· 26 citedOpen Access
The myeloperoxidase inhibitor mitiperstat (<scp>AZD4831</scp>) does not prolong the <scp>QT</scp> interval at expected therapeutic doses
Pharmacology Research & Perspectives·2024· 3 citedOpen Access
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus
British Journal of Clinical Pharmacology·2023· 3 citedOpen Access
A mechanistic modeling platform of <scp>SGLT2</scp> inhibition: Implications for type 1 diabetes
CPT Pharmacometrics & Systems Pharmacology·2023· 4 citedOpen Access
Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling
British Journal of Clinical Pharmacology·2022· 2 cited
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
The Journal of Clinical Pharmacology·2022· 7 citedOpen Access
Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance
British Journal of Clinical Pharmacology·2021· 8 citedOpen Access
Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations
British Journal of Clinical Pharmacology·2021· 9 citedOpen Access
Dapagliflozin pharmacokinetics is similar in adults with type 1 and type 2 diabetes mellitus
2021· 2 cited
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases
Journal of Pharmacokinetics and Pharmacodynamics·2021· 6 citedOpen Access
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019
The Journal of Clinical Pharmacology·2021· 14 cited
Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes
CPT Pharmacometrics & Systems Pharmacology·2021· 25 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

David W. Boulton(13), Weifeng Tang(13), Dinko Rekić(11), Susanne Johansson(9), Bengt Hamrén(9), Corina Dota(9), Robert C. Penland(8), Johanna Melin(7), Hans Ericsson(5), Tatiana A. Yakovleva(5), Victor Sokolov(5), Austin G. Stack(4), Nalina Dronamraju(4), Eva Johnsson(4), Fredrik Erlandsson(4), Linnéa Bergenholm(4), Sandra A. G. Visser(4), Robert Terkeltaub(3), Neil D. Evans(3), Michael J. Chappell(3)